Video

The Role of HER2 Alterations in NSCLC

Author(s):

Solange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Related Content
OncLive's OncFive: The Top 5 Oncology Articles of the Week
December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

Lung Cancer
December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC